<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EB5AD065-1283-45FD-9424-D6F7D54AF36A"><gtr:id>EB5AD065-1283-45FD-9424-D6F7D54AF36A</gtr:id><gtr:name>Antikor Biopharma Limited</gtr:name><gtr:address><gtr:line1>Imperial College London
Exhibition Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EB5AD065-1283-45FD-9424-D6F7D54AF36A" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>EB5AD065-1283-45FD-9424-D6F7D54AF36A</gtr:id><gtr:name>Antikor Biopharma Limited</gtr:name><gtr:address><gtr:line1>Imperial College London
Exhibition Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>94200.0</gtr:offerGrant><gtr:projectCost>125725.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3B395AE2-17DE-4C59-896C-DF1107A6388A"><gtr:id>3B395AE2-17DE-4C59-896C-DF1107A6388A</gtr:id><gtr:firstName>Mahendra</gtr:firstName><gtr:surname>Deonarain</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=131005"><gtr:id>44B6B4CF-B82E-4C61-A6FC-1B8E7EA65DF3</gtr:id><gtr:title>OptiLinked Antibody Drug Conjugates for Cancer Therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>131005</gtr:grantReference><gtr:abstractText>PhotoBiotics is a biotechnology company established from Imperial College London to develop antibody drug conjugates (ADCs) to treat cancer and other associated diseases. Its patented OptiLink platform enables high drug loading of small antibody fragments leading to enhanced formulation, tumour specificity, reduced side effects and high potency. In this TSB co-funded project, PhotoBiotics is exploring how the OptiLink platform can be used to target and reformulate an existing poorly soluble cancer chemotherapy drug - doxorubicin. The resulting drugs could be safer and easier to administer, with higher levels of potency due to their tumour specificity.</gtr:abstractText><gtr:fund><gtr:end>2014-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>94200</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">131005</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>